Knockdown of oncogenic KRAS in non-small cell lung cancers suppresses tumor growth and sensitizes tumor cells to targeted therapy.

@article{Sunaga2011KnockdownOO,
  title={Knockdown of oncogenic KRAS in non-small cell lung cancers suppresses tumor growth and sensitizes tumor cells to targeted therapy.},
  author={Noriaki Sunaga and David S. Shames and Luc Girard and Michael Peyton and Jill Everland Larsen and Hisao Imai and Junichi Soh and Mitsuo Sato and Noriko Yanagitani and Kyoichi Kaira and Yang Xie and Adi F. Gazdar and Masatomo Mori and John D. Minna},
  journal={Molecular cancer therapeutics},
  year={2011},
  volume={10 2},
  pages={336-46}
}
Oncogenic KRAS is found in more than 25% of lung adenocarcinomas, the major histologic subtype of non-small cell lung cancer (NSCLC), and is an important target for drug development. To this end, we generated four NSCLC lines with stable knockdown selective for oncogenic KRAS. As expected, stable knockdown of oncogenic KRAS led to inhibition of in vitro and in vivo tumor growth in the KRAS-mutant NSCLC cells, but not in NSCLC cells that have wild-type KRAS (but mutant NRAS). Surprisingly, we… CONTINUE READING
60 Citations
42 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 60 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 42 references

Mutational analysis of the HER2 gene in lung tumors from Caucasian Figure 3. (Continued)

  • F Buttitta, F Barassi, G Fresu, L Felicioni, A Chella, D Paolizzi
  • February 2011 345 on April
  • 2011
2 Excerpts

Similar Papers

Loading similar papers…